Osteoporosis, Postmenopausal Clinical Trial
Official title:
The Relationship Between Health Literacy, Exercise Habits, and Medication Adherence in Postmenopausal Osteoporosis Patients
Postmenopausal osteoporosis is characterized by low bone mass and increased fracture risk. Treatment includes exercise, nutrition, supplements, and medications like bisphosphonates, denosumab, or hormone replacement therapy. Lifestyle changes such as quitting smoking, reducing alcohol consumption, and preventing falls are also crucial. Despite effective treatments, adherence is low: 20-30% of patients don't start oral bisphosphonates, and 16-60% continue medications after one year. Exercise adherence rates are similarly low (14.3%-57.7%). This non-adherence imposes a significant clinical and economic burden. Health literacy (HL)-the ability to find, understand, and use health information-is vital for managing health but is understudied in relation to osteoporosis treatment adherence. This study aims to examine the relationship between HL, exercise habits, and medication adherence in postmenopausal osteoporosis patients. Understanding these factors can lead to effective interventions, improving patient adherence and health outcomes. The study will measure HL levels and their correlation with medication and exercise adherence, potentially informing health education programs and strategies to enhance treatment adherence. By doing so, it aims to improve health outcomes and healthcare system efficiency.
Postmenopausal osteoporosis is a common bone disease characterized by low bone mass, deterioration of bone tissue microarchitecture, and an increased risk of fractures. This condition results from the imbalance between bone formation and resorption due to decreased estrogen levels. Fractures, the feared complication of osteoporosis, make this condition a significant problem both clinically and from a public health perspective. In Europe, postmenopausal osteoporosis affects approximately 22 million women and causes over 3.5 million fragility fractures annually. Treatment options include regular exercise, healthy nutrition, calcium and vitamin D supplementation, and pharmacological treatments such as bisphosphonates, denosumab, or hormone replacement therapy. Additionally, quitting smoking, reducing alcohol consumption, and preventing falls are crucial in preventing osteoporosis and osteoporotic fractures. Despite the availability of safe and effective medications to reduce fracture risk, many patients either do not start treatment or do not adhere to it adequately. This non-adherence to treatment results in a significant clinical and economic burden. Following the prescription of medications, a substantial percentage of patients, around 20-30%, do not start taking oral bisphosphonates, and the continuation rate of osteoporosis medications over one year is reported to range from 16% to 60%. Furthermore, low levels of adherence to resistance/weight-bearing exercises (36.3%-54.4%) and physical activity (14.3%-57.7%) have been observed. Health literacy (HL) is defined as the capacity of individuals to find, understand, evaluate, and apply health-related information to prevent diseases, develop healthy eating behaviors, and improve their health. There are limited studies on the impact of health literacy on adherence to osteoporosis treatment in postmenopausal osteoporosis patients. However, no study has investigated the effect of HL on both medical treatment adherence and exercise adherence in postmenopausal osteoporosis patients. This study aims to investigate the relationship between health literacy, exercise habits, and medication adherence in postmenopausal osteoporosis patients. By identifying the factors leading to non-adherence to osteoporosis-preventive medications and regular exercise, effective interventions to enhance adherence to these treatments can be determined. This can result in better health outcomes for patients and increased efficiency within the healthcare system. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT03931109 -
Circulating miRNA in Primary Hyperparathyroidism
|
||
| Not yet recruiting |
NCT03232476 -
Effect of Mechanical Loading With PTH on Cortical Bone
|
Phase 4 | |
| Completed |
NCT02884401 -
Peri-implant Bone Changes in Post-menopausal Osteoporotic Women
|
N/A | |
| Completed |
NCT00073190 -
Patient- and Physician-Based Osteoporosis Education
|
Phase 1 | |
| Completed |
NCT00402441 -
Risedronate in the Prevention of Osteoporosis in Postmenopausal Women
|
Phase 4 | |
| Completed |
NCT03710889 -
Early Effects of Abaloparatide on Tissue-Based Indices of Bone Formation and Resorption
|
Phase 3 | |
| Completed |
NCT00010712 -
Effects of Black Cohosh on Menopausal Hot Flashes
|
Phase 2 | |
| Recruiting |
NCT05058976 -
Romosozumab Use to Build Skeletal Integrity
|
Phase 4 | |
| Active, not recruiting |
NCT05405894 -
Efficacy of Zoledronic Acid to Prevent Bone Loss Following Denosumab Discontinuation
|
||
| Recruiting |
NCT03337971 -
Nutritional Supplement and Bone Health in Post-Menopausal Women
|
N/A | |
| Completed |
NCT03701113 -
Milk Protein and Bone Health in Postmenopausal Women
|
N/A | |
| Completed |
NCT01381588 -
The Prevalence of Osteoporotic Vertebral Compression Fractures (OVCF) in Korean Post Menopausal Women
|
N/A | |
| Completed |
NCT00383422 -
Study Comparing Arzoxifene With Raloxifene in Women After Menopause With Osteoporosis
|
Phase 3 | |
| Completed |
NCT00549965 -
Satisfaction and Compliance of Risedronate in PMO
|
Phase 4 | |
| Completed |
NCT00035256 -
Sequential Use of Teriparatide and Raloxifene HCl in the Treatment of Postmenopausal Women With Osteoporosis
|
Phase 4 | |
| Completed |
NCT01386281 -
Julina Post-marketing Surveillance for Climacteric Symptoms in Japan
|
||
| Completed |
NCT05266261 -
Use of Ibandronate in Diabetic Patients
|
N/A | |
| Recruiting |
NCT04964388 -
Effect of GLP-1 Receptor Agonists on Trabecular Bone Score
|
Phase 2 | |
| Active, not recruiting |
NCT03623633 -
Comparative Antiresorptive Efficacy Discontinuation of Denosumab
|
Phase 4 | |
| Recruiting |
NCT05575167 -
Single or Repeat Zoledronate Versus Alendronate Following Denosumab (EUROpean Denosumab Effects Consolidation Study)
|